The National Comprehensive Cancer Network (NCCN) has updated its professional guidelines for prostate cancer to recommend biomarker-based testing for men with unfavorable intermediate- and high-risk disease. The Prolaris test from Myriad Genetics, Salt Lake City, was one of only two prognostic tests for prostate cancer recommended by NCCN for the new expanded indications and is now broadly recommended for use in low-, intermediate-, and high-risk disease.
“NCCN’s endorsement of Prolaris testing in unfavorable intermediate- and high-risk disease is a major step forward for men and will help in expanding access to testing,” says Todd D. Cohen, MD, vice president of medical affairs for urology at Myriad Genetics. “Recent data demonstrated the ability of Prolaris to determine which men will benefit from multimodality therapy and who can avoid unnecessary morbidity associated with aggressive treatment.”
In a recent study of 718 men presented at the American Society of Clinical Oncology genitourinary cancer symposium in San Francisco, Myriad demonstrated the ability of Prolaris to predict which prostate cancer patients with unfavorable intermediate- or high-risk disease would benefit from additional treatment. In the study, patients above the high-risk threshold saw a statistically significant benefit from multimodality therapy leading to a reduction in the risk of metastases, where patients below the high-risk threshold saw no statistical benefit from additional treatment and could avoid the morbidity associated with increased therapy.
Read more from Myriad Genetics.
